A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination AutologousCD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies (Lymphoma)
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at various times, whether your immune system becomes activated, whether your body produces antibodies (proteins produced by your immune system) against SYNCAR-001 and/or STK-009, and the effects of SYNCAR-001 + STK-009 on your cancer.
Ran Reshef, MD
|Are you at least 18 years old?
|Are you able to give informed consent?